
Rachel Reeves must slap VAT on private healthcare, warns ex-Labour leader Neil Kinnock
Rachel Reeves should slap VAT on private healthcare to raise billions for the NHS, ex-Labour leader Lord Neil Kinnock has said.
The prominent politician said Rachel Reeves should remove the VAT exemption in the same way she did with private schools in this autumn's Budget. He said the move would raise 'vital funding' for public services and be 'widely supported' by the public.
It comes as .
The Chancellor is battling to plug a hole in the public finances following recent Government U-turns on cuts to disability benefits and the winter fuel allowance. Labour is constrained by how it can raise money after pledging in the election not to hike income tax, national insurance or VAT.
But removing a VAT exemption on private healthcare could provide an opportunity for Ms Reeves to raise cash without breaking her election promise.
Lord Kinnock told the i newspaper: 'Introducing VAT on private health provision could provide vital funding for the NHS and social care.
'After 14 years of underinvestment, many people are turning to private healthcare not out of choice, but because they cannot afford to wait. This has increasingly led to unequal access to care. Ending the VAT exemption to generate much-needed revenue is a reasonable and widely supported step.'
Analysis by the Good Growth Foundation (GGF) think tank, which supports the policy, found more than £2billion could be raised by applying 20% VAT to private acute healthcare. This would excluding putting VAT on the use of private hospitals.
Private acute healthcare covers short-term care and treatment for illnesses or injuries but does not include things like optician and dental appointments. The GGF said the area of care was worth £12.4bn in 2024.
Some 55% of Brits support a 'windfall tax' on private healthcare firms, with 17% against it, according to a poll of 2,054 adults by the think tank in June.
Praful Nargund, GGF's founder, said: 'We are sleepwalking into a two-tier healthcare system, and we have to back our NHS.
'The NHS is in a dire state: from 8am GP scrambles to months-long waits for cancer care, this is simply not good enough. People are being forced to go private for care they should get for free.
'That's not a system in need of tweaks – it's a system on the brink, in need of major reform. A windfall tax on private healthcare would be a bold, fair first step to fund the innovation and change we need in the NHS.'
During the election, Labour pledged to scrap the VAT exemption enjoyed by private schools to pay for 6,500 new teachers for state schools. From January this year, all private education and boarding services became subject to VAT at the standard rate of 20%.
The Department for Education says ending tax breaks on private schools will help raise around £1.8billion per year by the 2029/30 financial year.
Education Secretary Bridget Phillipson has faced fury over the policy from right-wing parties. Critics claim it will put pressure on state schools as they will have to accept kids from families who can no longer afford private schools, if their provider chooses to hike fees to pay for the VAT uplift.
In December, Ms Phillipson said she had received abuse over the policy but added: 'I'll wear that as a badge of honour if it means that we drive up standards in state schools and invest in better life chances for our children.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Guardian
3 hours ago
- The Guardian
OpenAI stops ChatGPT from telling people to break up with partners
ChatGPT will not tell people to break up with their partner and will encourage users to take breaks from long chatbot sessions, under new changes to the artificial intelligence tool. OpenAI, ChatGPT's developer, said the chatbot would stop giving definitive answers to personal challenges and would instead help people to mull over problems such as potential breakups. 'When you ask something like: 'Should I break up with my boyfriend?' ChatGPT shouldn't give you an answer. It should help you think it through – asking questions, weighing pros and cons,' said OpenAI. The US company said new ChatGPT behaviour for dealing with 'high-stakes personal decisions' would be rolled out soon. OpenAI admitted this year that an update to ChatGPT had made the groundbreaking chatbot too agreeable and altered its tone. In one reported interaction before the change, ChatGPT congratulated a user for 'standing up for yourself' when they claimed they had stopped taking their medication and left their family – who the user had thought were responsible for radio signals emanating from the walls. In the blog post, OpenAI admitted that there had been instances where its advanced 4o model had not recognised signs of delusion or emotional dependency – amid concerns that chatbots are worsening people's mental health crises. The company said it was developing tools to detect signs of mental or emotional distress so ChatGPT can direct people to 'evidence-based' resources for help. A recent study by NHS doctors in the UK warned that AI programs could amplify delusional or grandiose content in users vulnerable to psychosis. The study, which has not been peer reviewed, said the programs' behaviour could be because the models were designed to 'maximise engagement and affirmation'. The study added that even if some individuals benefited from AI interactions, there was a concern the tools could 'blur reality boundaries and disrupt self-regulation'. OpenAI added that from this week it would send 'gentle reminders' to take a screen break to users engaging in long chatbot sessions, similar to screen-time features deployed by social media companies. OpenAI also said it had convened an advisory group of experts in mental health, youth development and human-computer-interaction to guide its approach. The company has worked with more than 90 doctors, including psychiatrists and paediatricians, to build frameworks for evaluating 'complex, multi-turn' chatbot conversations. 'We hold ourselves to one test: if someone we love turned to ChatGPT for support, would we feel reassured? Getting to an unequivocal 'yes' is our work,' said the blog post. The ChatGPT alterations were announced amid speculation that a more powerful version of the chatbot is imminent. On Sunday Sam Altman, OpenAI's chief executive, shared a screenshot of what appeared to be the company's latest AI model, GPT-5.

South Wales Argus
3 hours ago
- South Wales Argus
Treatment for advanced womb cancer ‘major step forward'
Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, can slow down cancer growth and improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment for the NHS in England marks a 'major step forward' in treatment for women with this type of cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26% compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. 'It is great news that this new treatment has been approved. 'It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. 'Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'


South Wales Guardian
3 hours ago
- South Wales Guardian
Treatment for advanced womb cancer ‘major step forward'
Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, can slow down cancer growth and improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment for the NHS in England marks a 'major step forward' in treatment for women with this type of cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26% compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. 'It is great news that this new treatment has been approved. 'It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. 'Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'